Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06375044 · ClinicalTrials.gov registry record · Phase 1
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Jiangsu Simcere Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 11
- Study locations
NCT06375044: Recruiting Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Jiangsu Simcere Pharmaceutical Co..
NCT06375044 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma that is actively recruiting participants, run by Jiangsu Simcere Pharmaceutical Co.. The registered enrollment target is 130 participants, below the 329-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (60% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06375044, a Phase 1 study of Relapsed or Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Jiangsu Simcere Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.
Primary Outcome
DLTs are defined as specific non-hematologic toxicity, or hematologic toxicity
Conditions Studied
Interventions
- DRUG SIM0500
Study Locations (11)
New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
- Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute - New York
Arizona
- Mayo Clinic Arizona - Phoenix
Florida
- Mayo Clinic Florida - Jacksonville
Massachusetts
- Dana Farber Cancer institution - Boston
Minnesota
- Mayo Clinic Rochester - Rochester
Beijing Municipality
- Beijing Chaoyang Hospital Capital Medical University - Beijing
Guangdong
- Sun Yat-sen University Cancer Center - Guangzhou
Henan
- Henan Cancer Hospital - Zhengzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2024-05-24 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 1 |
What NCT06375044 shows while recruiting
NCT06375044 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 329-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which SIM0500 is the first listed.
NCT06375044 lists 11 locations in 10 states (New York, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT06375044 about?
NCT06375044 is a clinical study titled "Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma". This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimi...
What is the current status of trial NCT06375044?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2024-05-24. Estimated completion is 2028-12-30.
What conditions does trial NCT06375044 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT06375044?
The interventions under investigation include: SIM0500 (DRUG).
Who is sponsoring clinical trial NCT06375044?
This trial is sponsored by Jiangsu Simcere Pharmaceutical Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06375044 being conducted?
This trial has 11 study locations across Arizona, Florida, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06375044's enrollment target sits among peer trials
130 7th of 10 higher than 4 of 10 other Relapsed or Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsed or Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
-
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
COMPLETED · Phase 1
-
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
COMPLETED · Phase 1
-
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI